Katherine N. Cahill, MD, Jillian C. Bensko, Joshua A

Slides:

Advertisements

Similar presentations

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Advertisements

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Von Ta, MD, Andrew A. White, MD

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Alalia Berry, MD, William W. Busse, MD

Tacrolimus reduces urinary excretion of leukotriene E4 and inhibits aspirin-induced asthma to threshold dose of aspirin Tetsuya Kawano, MD, Hiroto Matsuse,

Katharine M. Woessner, MD, FAAAAI, Andrew A. White, MD, FAAAAI

Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma Virginia Norris, MRCP, Lee Choong, BSc, Duyen Tran,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids Kittipong Maneechotesuwan, MD, PhD, Sirinya.

Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin- Exacerbated Respiratory Disease Neelam H. Shah, MD, Thomas R. Schneider, BA,

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome

David A. Khan, MD Journal of Allergy and Clinical Immunology

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Katherine N. Cahill, MD, Christina B

Analysis of basophil activation in patients with aspirin-exacerbated respiratory disease Chihiro Mitsui, MD, Keiichi Kajiwara, BSc, Emiko Ono, MD, PhD,

Badrul A. Chowdhury, MD, PhD

Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers Noritaka Higashi, MD, PhD, Haruhisa Mita, PhD,

Reply The Journal of Allergy and Clinical Immunology: In Practice

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature Jessica P. Rajan, MD, Nathan E. Wineinger,

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema Marek L.

Repeated Episodes of Anaphylaxis with Normal Serum Tryptase but Elevated Levels of Urinary Prostaglandin D2 Phillip Lieberman, MD The Journal of Allergy.

Brent E. Palmer, PhD, Douglas G. Mack, PhD, Allison K

Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center study Jeremy Waldram, MD, Kristen Walters,

Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease Katherine N. Cahill, MD, Katherine Murphy, BA,

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin- exacerbated respiratory disease Jacqueline J. Eastman, MD, Kellen.

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease Xin Feng, MD, Madison K. Ramsden, BS, Julie Negri,

Early decreases in blood eosinophil levels with reslizumab

Alcohol-induced Respiratory Symptoms Are Common in Patients With Aspirin Exacerbated Respiratory Disease Juan Carlos Cardet, MD, Andrew A. White, MD,

Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease Tanya M. Laidlaw, MD, Anya J. Cutler, Molly S.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Lisa G. Wood, PhD, Manohar L. Garg, PhD, Peter G. Gibson, MBBS

What is an “eosinophilic phenotype” of asthma?

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease Xin Feng, MD, Madison K. Ramsden, BS, Julie Negri,

Von Ta, MD, Andrew A. White, MD

Risk of oral food challenges

Hypersensitivity to aspirin: Common eicosanoid alterations in urticaria and asthma Lucyna Mastalerz, MD, PhD, Malgorzta Setkowicz, MD, Marek Sanak, MD,

Cindy Thamrin, PhD, Joel Zindel, Regula Nydegger, MD, Helen K

Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma Sally E. Wenzel, MD Journal of Allergy and Clinical.

Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma Kameran Daham, MD, PhD, Anna James, PhD,

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

News & Notes Journal of Allergy and Clinical Immunology

The GILL study: Glycerin-induced local reactions in immunotherapy

Systemic responses after bronchial aspirin challenge in sensitive patients with asthma Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,

Advances in pediatric asthma in 2007

Safety and efficacy of repeated monthly carboplatin desensitization

Natural history of cow’s milk allergy

Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids Kittipong Maneechotesuwan, MD, PhD, Sirinya.

Primary prevention of asthma and allergy

Analysis of basophil activation in patients with aspirin-exacerbated respiratory disease Chihiro Mitsui, MD, Keiichi Kajiwara, BSc, Emiko Ono, MD, PhD,

Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years Malgorzata Setkowicz, MD, PhD, Lucyna Mastalerz,

Presentation transcript:

Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory disease Katherine N. Cahill, MD, Jillian C. Bensko, Joshua A. Boyce, MD, Tanya M. Laidlaw, MD Journal of Allergy and Clinical Immunology Volume 135, Issue 1, Pages 245-252 (January 2015) DOI: 10.1016/j.jaci.2014.07.031 Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Rash observed after the provocative dose of aspirin in 3 group II patients with AERD. Journal of Allergy and Clinical Immunology 2015 135, 245-252DOI: (10.1016/j.jaci.2014.07.031) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Basal and post-aspirin (ASA) urinary LTE4 levels. Basal and aspirin-induced urinary LTE4 levels analyzed by using gas chromatography–mass spectrometry from control subjects with ATA (basal, n = 10; after aspirin, n = 5), group I patients with AERD (n = 23), and group II patients with AERD (n = 6) are shown. Data are expressed as means ± SEMs. ★P < .05 and ★★P < .01. Journal of Allergy and Clinical Immunology 2015 135, 245-252DOI: (10.1016/j.jaci.2014.07.031) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 PG levels at baseline and after aspirin (ASA). A, Basal (left panel) and post-aspirin (right panel) urinary PG levels in patients with ATA (basal, n = 10; after aspirin, n = 5), group I patients (n = 23), and group II patients (n = 6) are shown. B, Log2 of change from basal urinary PG levels induced by aspirin administration is shown for the 3 patient groups. Data are expressed as means ± SEMs. ★P < .05, ★★P < .01, and ★★★P < .001. Journal of Allergy and Clinical Immunology 2015 135, 245-252DOI: (10.1016/j.jaci.2014.07.031) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Basal urinary eicosanoid levels correlate with change in FEV1 during aspirin desensitization. Basal urinary LTE4 (A) and PGD-M (B) levels plotted against the corresponding percentage change in FEV1 during aspirin reaction for each patient with AERD are shown. The effect size, as determined by using the Pearson correlation coefficient, is denoted as an r value. Journal of Allergy and Clinical Immunology 2015 135, 245-252DOI: (10.1016/j.jaci.2014.07.031) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Effect of high-dose aspirin therapy on urinary eicosanoid levels in patients with AERD. Urinary eicosanoid levels of group I patients with AERD (n = 14) are shown at baseline before aspirin and after 650 mg of twice-daily aspirin therapy for 8 weeks. Data are expressed as means ± SEMs. ★★P < .01 and ★★★P < .001. Journal of Allergy and Clinical Immunology 2015 135, 245-252DOI: (10.1016/j.jaci.2014.07.031) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 6 Peripheral blood eosinophil counts increase on high-dose aspirin therapy. Blood eosinophil, basophil, and neutrophil counts (K/μL) for group I patients with AERD (n = 11) at baseline and during high-dose aspirin therapy are shown. Data are expressed as means ± SEMs. ★★P < .01. Journal of Allergy and Clinical Immunology 2015 135, 245-252DOI: (10.1016/j.jaci.2014.07.031) Copyright © 2014 American Academy of Allergy, Asthma & Immunology Terms and Conditions